Formoterol in Diabetes

The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.

NCT Number	NCT07022418
Lead Sponsor	Medical University of South Carolina Collaborators: Dialysis Clinic, Inc.
Conditions	Diabetic Nephropathies, Diabetic Kidney Disease
Enrollment	120 participants
Start Date	2025-12-01
Primary Completion	2026-12 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-02-05